Let's keep it simple. The false narratives are: 1)

Let's keep it simple. The false narratives are: 1) OM is included in the term sheet, and simultaneously 2) OM is not included in the term sheet because no one wants it.

Both false narratives are, well, false.

OM is not included in the term sheet. It is not something that is considered part of ulcerative proctitis or ulcerative sigmoiditis which is what the term sheet covers. It's not part of it, period.

As far as supposedly "not included because no one wants it" -- that is just plain absurd.

It's not included because it's not included.
The company may be withholding it from this term sheet because the company wants to develop it through Phase 3 by itself, to get more money later.
Or, there may be another prospective partner who is knee-deep in negotiations now.
Or, for all we know, there may be several companies who are all interested and the company is weighing options.
There are any number of scenarios -- but the idea that because a term sheet was signed for one type of application, therefore other applications have failed -- this is just absurd. And that is made even more clear by the fact that the prospective partner who signed the term sheet wants the right of first negotiation for other uses for Brilacidin.